Peroxisomal disorders

A neonate is born with a high forehead, a large fontanelle, profound hypotonia, and hepatomegaly, and within days develops seizures that do not respond. Down the corridor, a healthy-looking six-year-old boy who had been doing well at school becomes withdrawn, clumsy, and hard of hearing, and his brain MRI lights up with symmetric, gadolinium-enhancing white-matter change. In both rooms the unifying question is the same: is this a peroxisomal disorder, which one, and how fast does it move. The fellowship task is to split the bedside pattern into the biogenesis group or the single-enzyme group, confirm with the right biochemistry, and act before an irreversible window closes. ^{[2] [4]}

Overview & Definition

The peroxisome is a single-membrane organelle that carries out a small set of oxidative reactions the mitochondrion cannot manage: beta-oxidation of very-long-chain fatty acids, alpha-oxidation of phytanic acid, the early steps of plasmalogen synthesis, and steps of bile-acid synthesis. A peroxisomal disorder is what happens when one of these functions is lost — either because the whole organelle fails to assemble, or because a single enzyme or transporter within it is defective. The missing function, not the missing gene, drives the phenotype, which is why a child without any peroxisomes looks completely different from a boy who simply cannot import very-long-chain fatty acids into them. ^{[1] [6]}

Two mechanistic groups organise the entire topic. The first is the peroxisome biogenesis disorders — collectively the Zellweger spectrum — caused by recessive mutations in any of roughly fourteen PEX genes that encode the peroxins responsible for importing matrix proteins into the organelle. When peroxins fail, the organelle is empty or absent and every peroxisomal pathway collapses at once, producing the most severe phenotype in metabolic medicine. The second group is the single-enzyme or single-transporter deficiencies, in which the peroxisome is intact but one reaction is blocked; X-linked adrenoleukodystrophy, Refsum disease, and rhizomelic chondrodysplasia punctata sit here, and each behaves like its own disease. ^{[1] [3]}

The inheritance pattern matters because it changes counselling and who is at risk. The Zellweger spectrum, Refsum disease, and rhizomelic chondrodysplasia punctata are autosomal recessive, so a previously affected child reshapes the reproductive risk for every later pregnancy. X-linked adrenoleukodystrophy is the exception that dominates the exam: affected boys carry the full burden, carrier mothers may show a milder myelopathy in adulthood, and a single affected male sends ripples through every female relative. Naming the inheritance at the first consultation frames every later conversation about siblings, future children, and the wider family. ^{[4] [5]}

References12ShowHide

1. [1]Wanders RJA, Waterham HR. Biochemistry of mammalian peroxisomes revisited. Annu Rev Biochem, 2006.PMID 16756494
2. [2]Klouwer FCC, Berendse K, Engelen M, Wanders RJA, Ferdinandusse S, Poll-The BT. Zellweger spectrum disorders: clinical overview and management approach. Orphanet J Rare Dis, 2015.PMID 26627182
3. [3]Braverman NE, Raymond GV, Rizzo WB, Moser AB, Wilkinson ME, Stone EM, et al. Peroxisome biogenesis disorders in the Zellweger spectrum: An overview of current diagnosis and clinical care. Mol Genet Metab, 2016.PMID 26750748
4. [4]Moser HW, Mahmood A, Raymond GV. X-linked adrenoleukodystrophy. Nat Clin Pract Neurol, 2007.PMID 17342190
5. [5]Raymond GV, Moser AB, Fatemi A. X-linked adrenoleukodystrophy. GeneReviews, 1993.PMID 20301491
6. [6]Steinberg SJ, Raymond GV, Braverman NE, et al. Zellweger spectrum disorder. GeneReviews, 1993.PMID 20301621
7. [7]Klouwer FC, Huffnagel IC, Ferdinandusse S, et al. Clinical and biochemical pitfalls in the diagnosis of peroxisomal disorders. Neuropediatrics, 2016.PMID 27089543
8. [8]Wanders RJ, Klouwer FC, Ferdinandusse S, et al. Clinical and laboratory diagnosis of peroxisomal disorders. Methods Mol Biol, 2017.PMID 28409475
9. [9]Lee S, Clinard K, Young SP, et al. Evaluation of X-linked adrenoleukodystrophy newborn screening in North Carolina. JAMA Netw Open, 2020.PMID 32003821
10. [10]Bose M, Yergeau C, D'Souza Y, et al. Characterization of severity in Zellweger spectrum disorder by clinical findings: A scoping review. Cells, 2022.PMID 35741019
11. [11]Berendse K, Engelen M, Ferdinandusse S, et al. Zellweger spectrum disorders: clinical manifestations in patients surviving into adulthood. J Inherit Metab Dis, 2016.PMID 26287655
12. [12]Klouwer FCC, Koot BGP, Berendse K, et al. The cholic acid extension study in Zellweger spectrum disorders: Results and implications for therapy. J Inherit Metab Dis, 2019.PMID 30793331